Well, the Merck deal certainly muddies Schering-Plough's focus on relatively small matters, and their interest in making announcements. The people within SP who were most connected to those trials (who used to work for Organon), having survived one merger, may be preoccupied with whether they will survive this one, or be included in the 16,000 jobs to be culled. It doesn't mean everything has ground to a complete halt, or that any and all licensing activities are frozen, but it would be human nature for those people to have their attention diverted.
NeuroInvestment
News 
Market Data 
Discover 
AI
